Recent Updates
Recently added Catalysts
ACAD Positive Sentiment Score: 70/100

Acadia Pharmaceuticals to Participate at Upcoming May 2026 Investor Conferences

Key Takeaway: Acadia Pharmaceuticals has announced its participation in two upcoming investor conferences in May 2026. The first is the BofA Securities 2026 Health Care Conference, and the second is the RBC Capital Markets Global Healthcare Conference. Live webcasts of the events will be available on the company's website, ensuring accessibility for investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Acadia Pharmaceuticals is actively engaging with investors.
  • Participation in major healthcare conferences highlights company visibility.
  • The company is committed to innovation in neurological and rare diseases.

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences:
BofA Securities 2026 Health Care ConferenceFireside Chat: Tuesday, May 12, 2026 at 4:20 p.m. Pacific Time in Las Vegas, NV
2026 RBC Capital Markets Global Healthcare ConferenceFireside Chat: Tuesday, May 19, 2026 at 9:00 a.m. Eastern Time in New York, NY
Live webcasts will be accessible on the company’s website,acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.
About Acadia Pharmaceuticals
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us atacadia.comand follow us onLinkedInandX.
Investor Contact:Acadia Pharmaceuticals Inc.Al Kildani(858) 261-2872ir@acadia-pharm.com
Acadia Pharmaceuticals Inc.Jessica Tieszen(858) 261-2950ir@acadia-pharm.com

Frequently Asked Questions

When will Acadia Pharmaceuticals participate in investor conferences?

Acadia Pharmaceuticals will participate in two conferences on May 12 and May 19, 2026.

Where can I watch the live webcasts of the conferences?

Live webcasts will be available on Acadia's website under the investors section.

What is Acadia Pharmaceuticals' focus area?

Acadia focuses on innovative treatments for neurological and rare diseases.

What FDA-approved treatments does Acadia offer?

Acadia offers the first FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome.

Last updated: Apr 29, 2026